---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-009928"
form_type: "8-K"
ticker: "MGX"
cik: "0001785279"
company_name: "Metagenomi Therapeutics, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:55:05.641210+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Metagenomi renames to Metagenomi Therapeutics; hemophilia A program on track for IND in 2026

## Summary
- Name changed to Metagenomi Therapeutics, Inc. effective Jan 12, 2026; ticker MGX unchanged.
- Lead program MGX-001: pre-IND meeting completed; IND/CTA on track for Q4 2026.
- Preclinical data showed curative FVIII activity in NHPs with no off-target editing.
- Cash runway extended to Q4 2027 following strategic pipeline prioritization.
- Jian Irish appointed CEO as part of strategic evolution toward in vivo gene editing.

## SEC filing metadata
- accession: 0001193125-26-009928
- form_type: 8-K
- ticker: MGX
- cik: 0001785279
- company_name: Metagenomi Therapeutics, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785279/000119312526009928/0001193125-26-009928-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785279/000119312526009928/mgx-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-009928
- JSON: https://secwatch.observer/filing/0001193125-26-009928.json
- Plain text: https://secwatch.observer/filing/0001193125-26-009928.txt

## Source-grounded claims
- claim_id: 4e080e3afe3adaf957bb43e36b44a18f519e7c4e
  claim: Metagenomi Therapeutics, Inc.: Amended certificate of incorporation to change company name from Metagenomi, Inc. to Metagenomi Therapeutics, Inc (effective 2026-01-12).
  evidence_excerpt: filed a certificate of amendment to its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”), solely to change the Company’s name from “Metagenomi, Inc.” to “Metagenomi Therapeutics, Inc.” (the “Name Change”), which became effective at 12:01 a.m. Pacific Time on January 12, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1785279/000119312526009928/0001193125-26-009928-index.htm
- claim_id: 89d2a51d8baac8668600fc2870c3e636f1754151
  claim: Metagenomi Therapeutics, Inc.: Amended and restated bylaws solely to reflect the name change (effective 2026-01-12).
  evidence_excerpt: the Company’s Board also amended and restated its Amended and Restated Bylaws (as amended, the “Second Amended and Restated Bylaws”), effective on January 12, 2026, solely to reflect the Name Change.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1785279/000119312526009928/0001193125-26-009928-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.